Zobrazeno 1 - 10 of 140 pro vyhledávání: '"Jeffrey A. Tice"'
1
Akademický článek
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry
Autor: Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Publikováno v: npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which
Externí odkaz: https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80
Zobrazit plný text záznamu
2
Akademický článek
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial
Autor: Holly Keane, Yash S. Huilgol, Yiwey Shieh, Jeffrey A. Tice, Jeff Belkora, Karen Sepucha, W. Patrick Shibley, Tianyi Wang, Mandy Che, Deborah Goodman, Elissa Ozanne, Allison Stover Fiscalini, Laura J. Esserman
Publikováno v: npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Breast cancer risk reduction has been validated by large-scale clinical trials, but uptake remains low. A risk communication tool could provide personalized risk-reduction information for high-risk women. A low-literacy-friendly, visual, and
Externí odkaz: https://doaj.org/article/b0a1f180ec6b4596afc1f8abf9a66a74
Zobrazit plný text záznamu
4
Data from One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk
Autor: Diana L. Miglioretti, Jeffrey A. Tice, Brian L. Sprague, Charlotte C. Gard, Karla Kerlikowske
Background: One measure of Breast Imaging Reporting and Data System (BI-RADS) breast density improves 5-year breast cancer risk prediction, but the value of sequential measures is unknown. We determined whether two BI-RADS density measures improve th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d70a0204345cef9609a9e0e777f5ab5
https://doi.org/10.1158/1055-9965.c.6515850.v1
Zobrazit plný text záznamu
6
Data from The Effect of Change in Body Mass Index on Volumetric Measures of Mammographic Density
Autor: Brian L. Sprague, Serghei Malkov, Amir Pasha Mahmoudzadeh, Jeffrey A. Tice, John Shepherd, Lin Ma, Karla Kerlikowske, Lynnette Leidy Sievert, Nicholas G. Reich, Susan R. Sturgeon, Katherine W. Reeves, Vicki Hart
Background: Understanding how changes in body mass index (BMI) relate to changes in mammographic density is necessary to evaluate adjustment for BMI gain/loss in studies of change in density and breast cancer risk. Increase in BMI has been associated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38be771f42c734e1a49a0aded776ed19
https://doi.org/10.1158/1055-9965.c.6515871.v1
Zobrazit plný text záznamu
8
The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States
Autor: Olena Mandrik, James Fotheringham, Shijie Ren, Jeffrey A. Tice, Richard H. Chapman, Matthew D. Stevenson, Steven D. Pearson, Serina Herron-Smith, Foluso Agboola, Praveen Thokala
Publikováno v: Clin J Am Soc Nephrol
Background and objectives: Despite existing therapies, people with lupus nephritis progress to kidney failure and have reduced life expectancy. Belimumab and voclosporin are two new disease-modifying therapies recently approved for the treatment of l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78b96ac0b3fe7074f2da3df2aa6f2a5f
https://doi.org/10.2215/cjn.13030921
Zobrazit plný text záznamu
10
The effectiveness and value of belimumab and voclosporin for lupus nephritis
Autor: James Fotheringham, Steven D. Pearson, Jeffrey A. Tice, Olena Mandrik, Praveen Thokala
Publikováno v: Journal of Managed Care & Specialty Pharmacy. 27:1495-1499
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f7da023dbb2a4f777dc08527e614b22
https://doi.org/10.18553/jmcp.2021.27.10.1495
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje